-
公开(公告)号：US20170035744A1
公开(公告)日：2017-02-09
申请号：US15298748
申请日：2016-10-20
Applicant: AMGEN INC.
Inventor： Ning CHEN , Xiaoqi CHEN , Yinhong CHEN , Alan C. CHENG , Richard V. CONNORS , Jeffrey DEIGNAN , Paul John DRANSFIELD , Xiaohui DU , Zice FU , Julie Anne HEATH , Daniel HORNE , Jonathan HOUZE , Matthew R. KALLER , Aarif Yusuf KHAKOO , David John KOPECKY , Su-Jen LAI , Zhihua MA , Lawrence R. MCGEE , Julio C. MEDINA , Jeffrey T. MIHALIC , Nobuko NISHIMURA , Steven H. OLSON , Vatee PATTAROPONG , Gayathri SWAMINATH , Xiaodong WANG , Kevin YANG , Wen-Chen YEH , Mikkel V. DEBENEDETTO , Robert P. FARRELL , Simon J. HEDLEY , Ted C. JUDD , Frank KAYSER
IPC: A61K31/4439 , C07D239/30 , C07D241/18 , C07D213/61 , A61K31/695 , A61K31/444 , A61K31/497 , A61K31/437 , A61K31/501 , A61K45/06 , C07C311/13 , C07D241/12 , C07D239/34 , C07D295/16 , A61K31/506 , C07D239/26
CPC classification number: A61K31/506 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/513 , A61K31/695 , A61K45/06 , C07B57/00 , C07B59/002 , C07B2200/05 , C07B2200/07 , C07C311/13 , C07D211/54 , C07D213/61 , C07D213/71 , C07D213/82 , C07D239/26 , C07D239/30 , C07D239/34 , C07D241/12 , C07D241/18 , C07D241/24 , C07D249/08 , C07D295/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F7/08
Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
-
2.发明申请HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER 有权作为MDM2抑制剂治疗癌症的异氟醚化合物公开(公告)号：US20160039774A1
公开(公告)日：2016-02-11
申请号：US14774645
申请日：2014-03-13
Applicant: AMGEN INC.
Inventor： Ana GONZALEZ BUENROSTRO , Yihong LI , Julio C. MEDINA , Steven H. OLSON
IPC: C07D265/32
CPC classification number: C07D265/32 , C07D413/06 , C07D417/06
Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).
Abstract translation: 本发明提供式（I）的MDM2抑制剂化合物或其药学上可接受的盐，其中变量如上所定义，哪些化合物可用作治疗剂，特别是用于治疗癌症。 本发明还涉及含有式（I）的MDM2抑制剂的药物组合物。
-
公开(公告)号：US20230052348A1
公开(公告)日：2023-02-16
申请号：US17501075
申请日：2021-10-14
Applicant: AMGEN INC.
Inventor： Sean P BROWN , David Karl BEDKE , Michael R. DEGRAFFENREID , Jiasheng FU , Zhinghong LI , Felix GONZALEZ LOPEZ DE TURISO , Ana GONZALEZ BUENROSTRO , Michael W. GRIBBLE JR. , Michael G. JOHNSON , Todd J. KOHN , Kexue LI , Yunxiao LI , Mike Elias LIZARZABURU , Yosup REW , Joshua TAYGERLY , Yingcai WANG , Xuelei YAN , Ming YU , Jiang ZHU , Manuel ZANCANELLA , Xian Yun JIAO , Liusheng ZHU , Xianghong WANG , Julio C. MEDINA , Jason A. DUQUETTE , Jonathan B. HOUZE , Marc VIMOLRATANA , Mario G. CARDOZO , Alan C. CHENG
IPC: C07D513/10 , C07D513/20 , C07D515/10
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
-
公开(公告)号：US20210230189A1
公开(公告)日：2021-07-29
申请号：US16078152
申请日：2017-02-24
Applicant: AMGEN INC.
Inventor： Sean P. BROWN , David Karl BEDKE , Micheal R. DEGRAFFENREID , Jiasheng FU , Zhihong LI , Felix GONZALEZ LOPEZ TURISO , Ana GONZALEZ BUENROSTRO , Micheal W. GRIBBLE, JR. , Micheal G. JOHNSON , Todd J. KOHN , Kexue LI , Yunxiao LI , Mike Elias LIZARZABURU , Yosup REW , Joshua TAYGERLY , Yingcal WANG , Xuelei YAN , Ming YU , Jiang ZHU , Manuel ZANCANELLA , Xian Yun JIAO , Liusheng ZHU , Xianghong WANG , Julio C. MEDINA , Jason A. DUQUETTE , Jonathan B. HOUZE , Marc VIMOLRATANA , Marlo G. CARDOZO , Alan C. CHENG
IPC: C07D513/10 , C07D515/10 , C07D513/20
Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
-
公开(公告)号：US20170144971A1
公开(公告)日：2017-05-25
申请号：US15412804
申请日：2017-01-23
Applicant: AMGEN INC.
Inventor： Michael D. BARTBERGER , Ana GONZALEZ BUENROSTRO , Hilary Plake BECK , Xiaoqi CHEN , Richard Victor CONNORS , Jeffrey DEIGNAN , Jason A. DUQUETTE , John EKSTEROWICZ , Benjamin FISHER , Brian M. FOX , Jiasheng FU , Zice FU , Felix GONZALEZ LOPEZ DE TURISO , Michael W. GRIBBLE, Jr. , Darin J. GUSTIN , Julie A. HEATH , Xin HUANG , XianYun JIAO , Michael G. JOHNSON , Frank KAYSER , David John KOPECKY , SuJen LAI , Yihong LI , Zhihong LI , Jiwen LIU , Jonathan D. LOW , Brian S. LUCAS , Zhihua MA , Lawrence R. MCGEE , Joel MCINTOSH , Dustin L. MCMINN , Julio C. MEDINA , Jeffrey Thomas MIHALIC , Steven H. OLSON , Yosup REW , Phillip M. ROVETO , Daqing SUN , Xiaodong WANG , Yingcai WANG , Xuelei YAN , Ming YU , Jiang ZHU
IPC: C07D211/76 , C07D417/12 , C07D413/06 , C07D471/10 , C07D409/04 , C07D417/06 , C07D405/04 , C07D401/04 , C07D279/02 , C07D401/12 , C07D491/08 , C07D498/08 , C07D409/12 , C07D405/12 , C07D417/14 , C07D498/20 , C07D401/06
CPC classification number: C07D211/76 , C07D221/20 , C07D279/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/04 , C07D405/12 , C07D407/04 , C07D407/06 , C07D409/04 , C07D409/12 , C07D413/06 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/10 , C07D491/08 , C07D491/153 , C07D498/08 , C07D498/14 , C07D498/20
Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20160137667A1
公开(公告)日：2016-05-19
申请号：US15008342
申请日：2016-01-27
Applicant: AMGEN INC.
Inventor： Michael D. BARTBERGER , Ana GONZALEZ BUENROSTRO , Hilary Plake BECK , Xiaoqi CHEN , Richard Victor CONNORS , Jeffrey DEIGNAN , Jason A. DUQUETTE , John EKSTEROWICZ , Benjamin FISHER , Brian M. FOX , Jiasheng FU , Zice FU , Felix GONZALEZ LOPEZ DE TURISO , Michael W. GRIBBLE, JR. , Darin J. GUSTIN , Julie A. HEATH , Xin HUANG , XianYun JIAO , Michael G. JOHNSON , Frank KAYSER , David John KOPECKY , SuJen LAI , Yihong LI , Zhihong LI , Jiwen LIU , Jonathan D. LOW , Brian S. LUCAS , Zhihua MA , Lawrence R. MCGEE , Joel MCINTOSH , Dustin L. MCMINN , Julio C. MEDINA , Jeffrey Thomas MIHALIC , Steven H. OLSON , Yosup REW , Phillip M. ROVETO , Daqing SUN , Xiaodong WANG , Yingcai WANG , Xuelei YAN , Ming YU , Jiang ZHU
IPC: C07D498/14 , C07D221/20 , C07D471/10
CPC classification number: C07D211/76 , C07D221/20 , C07D279/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/04 , C07D405/12 , C07D407/04 , C07D407/06 , C07D409/04 , C07D409/12 , C07D413/06 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/10 , C07D491/08 , C07D491/153 , C07D498/08 , C07D498/14 , C07D498/20
Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Abstract translation: 本发明提供了式I的MDM2抑制剂化合物，其中变量如上所定义，哪些化合物可用作治疗剂，特别是用于治疗癌症。 本发明还涉及含有MDM2抑制剂的药物组合物。
-
公开(公告)号：US20180354918A1
公开(公告)日：2018-12-13
申请号：US16048677
申请日：2018-07-30
Applicant: AMGEN INC.
Inventor： Michael D. BARTBERGER , Hilary Plake BECK , Michael R. DEGRAFFENREID , Brian M. FOX , Felix GONZALEZ LOPEZ DE TURISO , Lisa D. JULIAN , Frank KAYSER , Julio C. MEDINA , Steven H. OLSON , Yosup REW , Philip M. ROVETO , Daqing SUN , Xuelei YAN
IPC: C07D265/32 , C07D413/06 , C07D413/04 , C07D279/12 , C07D487/04
CPC classification number: C07D265/32 , C07D279/12 , C07D413/04 , C07D413/06 , C07D487/04
Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
-
公开(公告)号：US20180319773A1
公开(公告)日：2018-11-08
申请号：US16033632
申请日：2018-07-12
Applicant: AMGEN INC.
Inventor： Ning CHEN , Xiaoqi CHEN , Yinhong CHEN , Alan C. CHENG , Richard V. CONNORS , Jeffrey DEIGNAN , Paul John DRANSFIELD , Xiaohui DU , Zice FU , Julie Anne HEATH , Daniel B. HORNE , Jonathan HOUZE , Matthew R. KALLER , Aarif Yusuf KHAKOO , David John KOPECKY , Su-Jen LAI , Zhihua MA , Lawrence R. MCGEE , Julio C. MEDINA , Jeffrey T. MIHALIC , Nobuko NISHIMURA , Steven H. OLSON , Vatee PATTAROPONG , Gayathri SWAMINATH , Xiaodong WANG , Kevin YANG , Wen-Chen YEH , Mikkel V. DEBENEDETTO , Robert P. FARRELL , Simon J. HEDLEY , Ted C. JUDD , Frank KAYSER
IPC: C07D401/14 , C07D401/12 , A61K31/437 , C07D417/14 , A61K45/06 , C07B57/00 , C07B59/00 , C07D211/54 , C07D213/71 , C07D213/82 , C07D239/26 , C07D239/30 , C07D241/12 , C07D241/24 , C07D249/08 , C07D471/04 , C07D413/14 , C07D413/04 , C07D401/04 , C07D213/61 , C07D239/34 , C07D241/18 , C07F7/08 , C07D295/16 , C07C311/13 , A61K31/695 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/513 , C07D405/14
CPC classification number: C07D401/14 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/513 , A61K31/695 , A61K45/06 , C07B57/00 , C07B59/002 , C07B2200/05 , C07B2200/07 , C07C311/13 , C07D211/54 , C07D213/61 , C07D213/71 , C07D213/82 , C07D239/26 , C07D239/30 , C07D239/34 , C07D241/12 , C07D241/18 , C07D241/24 , C07D249/08 , C07D295/16 , C07D401/04 , C07D401/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F7/08
Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
-
公开(公告)号：US20170044131A1
公开(公告)日：2017-02-16
申请号：US15298434
申请日：2016-10-20
Applicant: AMGEN INC.
Inventor： Ning CHEN , Xiaoqi CHEN , Yinhong CHEN , Alan C. CHENG , Richard V. CONNORS , Jeffrey DEIGNAN , Paul John DRANSFIELD , Xiaohui DU , Zice FU , Julie Anne HEATH , Daniel B. HORNE , Jonathan HOUZE , Matthew R. KALLER , Aarif Yusuf KHAKOO , David John KOPECKY , Su-Jen LAI , Zhihua MA , Lawrence R. MCGEE , Julio C. MEDINA , Jeffrey T. MIHALIC , Nobuko NISHIMURA , Steven H. OLSON , Vatee PATTAROPONG , Gayathri SWAMINATH , Xiaodong WANG , Kevin YANG , Wen-Chen YEH , Mikkel V. DEBENEDETTO , Robert P. FARRELL , Simon J. HEDLEY , Ted C. JUDD , Frank KAYSER
IPC: C07D401/04 , A61K45/06 , C07D401/14 , A61K31/506 , C07D417/14 , A61K31/444 , A61K31/497 , A61K31/513 , C07D471/04 , A61K31/4439 , C07D413/14
CPC classification number: A61K31/506 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/513 , A61K31/695 , A61K45/06 , C07B57/00 , C07B59/002 , C07B2200/05 , C07B2200/07 , C07C311/13 , C07D211/54 , C07D213/61 , C07D213/71 , C07D213/82 , C07D239/26 , C07D239/30 , C07D239/34 , C07D241/12 , C07D241/18 , C07D241/24 , C07D249/08 , C07D295/16 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07F7/08
Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
-
10.发明申请CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开CIS-MORPHOLINONE和其他化合物作为MDM2抑制剂治疗癌症公开(公告)号：US20160002185A1
公开(公告)日：2016-01-07
申请号：US14768529
申请日：2014-02-18
Applicant: AMGEN INC.
Inventor： Michael D. BARTBERGER , Hilary Plake BECK , Michael R. DEGRAFFENREID , Brian M. FOX , Felix GONZALEZ LOPEZ DE TURISO , Lisa D. JULIAN , Frank KAYSER , Julio C. MEDINA , Steven H. OLSON , Yosup REW , Philip M. ROVETO , Daqing SUN , Xuelei YAN
IPC: C07D265/32 , C07D413/04 , C07D413/06 , C07D487/04 , C07D279/12
CPC classification number: C07D265/32 , C07D279/12 , C07D413/04 , C07D413/06 , C07D487/04
Abstract: The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
Abstract translation: 本发明提供式（I）的MDM2抑制剂化合物或其药学上可接受的盐，其中变量如上所定义，哪些化合物可用作治疗剂，特别是用于治疗癌症。 本发明还涉及含有MDM2抑制剂的药物组合物。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.039 seconds)
